Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 828 across all filing types
Latest filing 2023-01-12 Report Publication Anno…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "ADOCIA annonce son calendrier financier pour l'année 2023" (ADOCIA announces its financial calendar for 2023). It explicitly lists the dates for future publications, such as the 2022 annual results, Q1 2023 revenue, half-year results, and Q3 2023 revenue. This document is not the actual financial report (like 10-K or IR) but an announcement detailing *when* those reports will be released. According to Rule 2 (The "MENU VS MEAL" Rule), a document announcing the publication of other reports, especially when it's a short announcement, should be classified as a Report Publication Announcement (RPA).
2023-01-12 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a short press release announcing the company's financial calendar for 2023. It lists dates for the publication of the 2022 financial statements, Q1, Q2, and Q3 revenues, and mid-year statements. Crucially, it does not contain the actual financial statements or reports themselves, but rather announces *when* those reports will be published. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating that reports will be published or attached qualifies as a Report Publication Announcement (RPA). The document length (4120 chars) supports this interpretation, as it is an announcement, not the comprehensive report itself.
2023-01-12 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release announcing positive results from a Phase 1 clinical study for BioChaperone® Lispro, developed by Adocia and partnered with Tonghua Dongbao. It details clinical progress, market potential in China, and financial agreements (upfront fees, milestones, royalties). This type of announcement, focusing on specific operational or clinical achievements rather than comprehensive annual financials (10-K) or standard quarterly results (ER/IR), fits best under a general announcement category. Since it is a specific operational update that doesn't fit ER, IR, CAP, or LTR, and it is not a presentation (IP) or a transcript (CT), it is classified as a general Regulatory Filing (RNS) as it is a formal communication to the market regarding a significant development, often required by listing rules, which serves as a broad category for non-standard disclosures. FY 2021
2022-12-29 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release titled "ADOCIA annonce les résultats positifs d'une étude de Phase 1 sur BioChaperone® Lispro avec son partenaire Tonghua Dongbao". It details clinical trial results, partnership updates, financial implications (licensing payments), and future regulatory steps (submission for marketing authorization in China). This content is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses on announcing specific, positive results from a clinical study and partnership progress, it aligns best with the 'Earnings Release' (ER) category, which often includes key operational highlights outside of formal quarterly financial statements (like 10-Q or IR). It is not a full Annual Report (10-K), a transcript (CT), or a formal regulatory filing like a DVA or DIRS. Given the nature of announcing key operational/clinical progress, ER is the most appropriate fit among the provided options, although it could also be considered a Regulatory Filing (RNS) if no other category fit well. However, the focus on 'results' points towards ER. FY 2022
2022-12-29 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is titled "ADOCIA Announces its Participation at Upcoming Investor Conferences in January 2023." It details specific investor events (ODDO BHF Forum, JPM 2023, Biotech Showcase) where management will present company news and outlook. This content is a direct announcement about management's schedule for engaging with the financial community, which aligns best with an Investor Presentation (IP) or a general announcement. However, since it is specifically announcing management's planned participation and presentations at external investor conferences, it is a form of investor relations communication. Given the options, it is not a formal financial report (10-K, IR, ER), nor is it a proxy (DEF 14A) or a dividend notice (DIV). It is an announcement about management's investor outreach activities. While it mentions a presentation at Biotech Showcase, the document itself is the announcement of participation, not the presentation slides. The closest fit among the specific categories is Investor Presentation (IP) if we interpret this as the material leading up to or summarizing those engagements, but more accurately, it is a general announcement about investor relations activities. Since it is a press release announcing management's schedule for meeting investors and presenting updates, it falls under general investor communication. Given the choices, and recognizing it's a press release about future investor engagement, it is most closely related to Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if no better fit exists. Since it details management's plan to present strategy and progress to investors, IP is a strong candidate, but because it is an announcement *about* attending events rather than the presentation itself, and it's a standard press release format, RNS (Regulatory Filings/General Announcement) is often used for such non-standard, non-periodic corporate updates. However, the content is highly focused on investor engagement and outlook review. Let's re-evaluate: It announces management will review news and outlook. This is a precursor to or summary of investor meetings. If we must choose a specific type, 'IP' implies the presentation material itself. 'RPA' is for announcing the publication of a report. 'RNS' is the general fallback. Given the focus on investor meetings and presentations, and the short length (3928 chars), it functions as a general corporate update. I will classify it as RNS as it is a general press release announcing participation in external events, which doesn't fit the specific financial report types.
2022-12-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) dated December 21, 2022. The content announces Adocia's participation in several upcoming investor conferences in January 2023 (ODDO BHF Forum, JPM 2023, Biotech Showcase). It details the management's intention to discuss company news and outlook at these events. This is a communication intended to inform investors and the market about future engagement and presentations, rather than being a full financial report (like 10-K or IR), an earnings release (ER), or a formal proxy/governance document. Since it is an announcement about future investor engagement and presentations, it most closely aligns with Investor Presentation (IP) materials or, given its format as a press release announcing participation in investor events, it could be classified as a general Investor Relations communication. However, since the core purpose is to announce participation in investor meetings and conferences where presentations will occur, 'Investor Presentation' (IP) is a strong candidate, although 'Regulatory Filings' (RNS) is often used for general press releases that don't fit other specific categories. Given the focus on upcoming investor meetings and presentations, 'IP' is plausible, but the document itself is an announcement *about* presentations, not the presentation slides themselves. The document is short and serves as a general market update regarding investor outreach. Based on the definitions, this is a general announcement related to investor relations activities. Since there isn't a specific code for 'Investor Event Announcement', and it's not a formal report, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback for a press release detailing future investor engagement schedules.
2022-12-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.